Background: Adult-onset Still's disease (AOSD), a rare autoinflammatory disorder, resembles systemic juvenile idiopathic arthritis (SJIA). The superimposable systemic clinical features of AOSD and SJIA suggest both clinical phenotypes represent the same disease continuum with different ages of onset. To further characterize the similarity between AOSD and SJIA at the molecular level, 2 previously identified response gene sets in SJIA were used to investigate how genes that respond to interleukin (IL)-1β inhibition with canakinumab in SJIA patients behave in AOSD patients with active disease prior to IL-1β targeting therapy, relative to healthy subjects. Findings: All genes downregulated in SJIA patients following canakinumab treatment were ...
Background: Canakinumab is a human anti-interleukin-1β (IL-1β) monoclonal antibody neutralizing IL-1...
Still's disease in children (systemic-onset juvenile idiopathic arthritis, SoJIA) and in adults (adu...
Background: Canakinumab is a human anti-interleukin-1β (IL-1β) monoclonal antibody neutralizing IL-1...
Background: Adult-onset Still's disease (AOSD),a rare autoinflammatory disorder, resembles systemic ...
Background: Adult-onset Still's disease (AOSD),a rare autoinflammatory disorder, resembles systemic ...
Background: Adult-onset Still's disease (AOSD),a rare autoinflammatory disorder, resembles systemic ...
Background: Adult-onset Still's disease (AOSD),a rare autoinflammatory disorder, resembles systemic ...
Background: Adult-onset Still's disease (AOSD),a rare autoinflammatory disorder, resembles systemic ...
Background: Adult-onset Still’s disease (AOSD), a rare autoinflammatory disorder, resembles systemic...
Adult-onset Still's disease (AOSD) is a rare inflammatory disease characterized by the classical tri...
Background: Canakinumab is a human anti-interleukin-1\u3b2 (IL-1\u3b2) monoclonal antibody neutraliz...
BACKGROUND: Canakinumab is a human anti-interleukin-1β (IL-1β) monoclonal antibody neutralizing IL-1...
Background: Canakinumab is a human anti-interleukin-1β (IL-1β) monoclonal antibody neutralizing IL-1...
BACKGROUND: Canakinumab is a human anti-interleukin-1β (IL-1β) monoclonal antibody neutralizing IL-1...
Adult-onset Still's disease (AOSD) is a rare inflammatory disease characterized by the classical tri...
Background: Canakinumab is a human anti-interleukin-1β (IL-1β) monoclonal antibody neutralizing IL-1...
Still's disease in children (systemic-onset juvenile idiopathic arthritis, SoJIA) and in adults (adu...
Background: Canakinumab is a human anti-interleukin-1β (IL-1β) monoclonal antibody neutralizing IL-1...
Background: Adult-onset Still's disease (AOSD),a rare autoinflammatory disorder, resembles systemic ...
Background: Adult-onset Still's disease (AOSD),a rare autoinflammatory disorder, resembles systemic ...
Background: Adult-onset Still's disease (AOSD),a rare autoinflammatory disorder, resembles systemic ...
Background: Adult-onset Still's disease (AOSD),a rare autoinflammatory disorder, resembles systemic ...
Background: Adult-onset Still's disease (AOSD),a rare autoinflammatory disorder, resembles systemic ...
Background: Adult-onset Still’s disease (AOSD), a rare autoinflammatory disorder, resembles systemic...
Adult-onset Still's disease (AOSD) is a rare inflammatory disease characterized by the classical tri...
Background: Canakinumab is a human anti-interleukin-1\u3b2 (IL-1\u3b2) monoclonal antibody neutraliz...
BACKGROUND: Canakinumab is a human anti-interleukin-1β (IL-1β) monoclonal antibody neutralizing IL-1...
Background: Canakinumab is a human anti-interleukin-1β (IL-1β) monoclonal antibody neutralizing IL-1...
BACKGROUND: Canakinumab is a human anti-interleukin-1β (IL-1β) monoclonal antibody neutralizing IL-1...
Adult-onset Still's disease (AOSD) is a rare inflammatory disease characterized by the classical tri...
Background: Canakinumab is a human anti-interleukin-1β (IL-1β) monoclonal antibody neutralizing IL-1...
Still's disease in children (systemic-onset juvenile idiopathic arthritis, SoJIA) and in adults (adu...
Background: Canakinumab is a human anti-interleukin-1β (IL-1β) monoclonal antibody neutralizing IL-1...